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Abstract
During the G2 phase of the cell cycle, the Aurora-A kinase plays an important role in centrosome maturation and
progression to mitosis. In this study, we show in colorectal cell lines that Aurora-A expression is downregulated in
response to topoisomerase I inhibition. Using chromatin immunoprecipitation assays, we have observed that the
Myc transcription factor and its Max binding partner are associated with the Aurora-A promoter during the G2
phase of the cell cycle. RNA interference experiments indicated that Myc is involved in the regulation of the Aur-
ora-A gene. Following topoisomerase I inhibition, the expression of Myc decreased whereas Mad was upregulated,
and the association of Myc and Max with the promoter of the kinase was inhibited. In parallel, an increased asso-
ciation of Mad and Miz-1 was detected on DNA, associated with an inhibition of the recruitment of transcriptional
coactivators. Interestingly, a gain of H3K9 trimethylation and HP1g recruitment was observed on the Aurora-A pro-
moter following sn38 treatment, suggesting that this promoter is located within SAHF foci following genotoxic
treatment. Since Aurora-A is involved in centrosome maturation, we observed as expected that topoisomerase I
inhibition prevented centrosome separation but did not affect their duplication. As a consequence, this led to G2
arrest and senescence induction.
These results suggest a model by which the Aurora-A gene is inactivated by the G2 checkpoint following topoi-
somerase I inhibition. We therefore propose the hypothesis that the coordinated overexpression of Myc and Aur-
ora-A, together with a downregulation of Mad and Miz-1 should be tested as a prognosis signature of poor
responses to topoisomerase I inhibitors.
Background
The response to genotoxic treatments relies to a large
extent on the activation of the ATM and ATR kinases
and on the consequent upregulation of chk1 and chk2
signaling [1-3]. Among numerous substrates, this signal-
ing network leads to the activation and stabilization of
the p53 pathway which induces apoptosis or cell cycle
arrest [4]. In addition to this protective pathway, others
checkpoints are also involved in the control of the pro-
gression towards mitosis. At the G1/S transition, chk1/2
activation promotes the degradation of cdc25A by the
SCF
bTCRP complex, leading to cdk2 inactivation and G1
phase arrest [5]. During G2 and mitosis, the inhibition
of cdc25C by chk1/2 induces the inactivation of cyclin
B-cdk1 complexes [6,7], whereas the BubR1, Mad1 or
Mad2 proteins can prevent anaphase following spindle
checkpoint activation [8].
In association with the cyclin B-cdk1 complexes and
cdc25C, the Aurora-A serine/threonine kinase is also
essential for progression to mitosis [9,10]. This protein
localizes in early G2 to duplicated centrosomes where it
plays an important role in their maturation, separation
and in the consequent assembly of the spindle appara-
tus. Illustrating its essential role in spindle organization,
the inactivation of Aurora-A leads to the generation of
spindle defects, mitotic catastrophe and aneuploidy
[10,11]. Importantly, a high expression of the kinase,
often due to gene amplification at 20q13, has been
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ovarian, gastric, pancreatic and colorectal cancers [9]. In
addition, the overexpression of Aurora-A transforms
NIH3T3 fibroblasts, probably as a consequence of
abnormal mitosis and inactivation of the p53 tumor
suppressor gene [12]. An abnormal expression of this
kinase is therefore believed to play an important role in
cell transformation and genetic instability.
Despite recent studies [13], the regulation of Aurora-A
during DNA damage remains most of the time to be
characterized. In this study, we show that topoisomerase
I inhibitors, one the main drug used in the treatment of
colorectal cancers [14,15], induced a downregulation of
Aurora-A expression and prevented centrosome separa-
tion. In normal conditions, we found that the Myc tran-
scription factor binds to the promoter of this gene in
association with Max. Following topoisomerase I inhibi-
tion, Myc/Max binding is inhibited, Mad and Miz-1
associate with this promoter and this is associated with
transcriptional downregulation.
Altogether, these results indicate that Aurora-A is
downregulated in response to topoisomerase I inhibi-
tion. We propose that this inhibition plays an important
role during the G2 checkpoint in parallel to p53 induc-
tion and cdc25C inactivation.
Methods
Reagents
Polyclonal anti-phospho p53 (SC-11764-R), anti-c-myc
(SC-764), anti-p21waf1 (SC-397), monoclonal anti-p53
(SC-98), anti-max (C17) (SC-197), anti-mad1 (C19) (SC-
222), anti-CBP (A22) (SC369), anti-RNA polymerase II
(N20) (SC899), anti-HP1 (S-19) and anti-miz1 (H190)
(SC-22837) were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz). Monoclonal anti-a and g-tubulin were
obtained from Sigma, anti-H3K9me3 (07-442) and anti-
H3-Ac (06-599) were from Upstate. All statistical analy-
sis have been performed with the Graphpad software.
Primers
Total RNA was isolated from cell lines with TRIzol
reagent (Invitrogen) and expression was measured by
real time PCR analysis using GADPH or RPLPO as a
normalization standards. The following primers were
used:
Aurora A: For 5′-GATCAGCTGGAGAGCTTAAA-3′,
Rev 5′-GAGGCTTCCCAACTAAAAAT-3′; c-Myc: For
5′-ATTCTCTGCTCTCCTCGAC-3′,R e v5 ′-GTAGTTG
TGCTGATGTGTGG-3′;M a x :F o r5 ′-ACGAAAACG
TGGGACCACATC-3′,R e v5 ′-GTGTGTGGTTTTT
CCCGCATAT-3′;M a d :F o r5 ′-GGTTCGGATGAA-
CATCCAG-3′,R e v5 ′-GGCATCTCTGTCCTTGTTA
TTGT-3′;M i z - 1 :F o r5 ′-GGCAAACTGTCAG AAAA-
GAGTAGC-3′,R e v5 ′-CGCTGCTGGTTCAGC TGTT-
3′; p21WAF1: For 5′-GCTCCTTCCCATCGCTGTCA-3′
Rev 5′-TCACCCTGCCCAACCTTAGA-3′; GAPDH: For
5′-GAAGGTGAAGGTCGGAGTC-3′,R e v5 ′-GAA-
GATGGTGATGGGATTTC-3; 3′ RPLPO: For 5′-AACC
CAGCTCTGGAGAAACT-3′ and Rev 5′-CCCCTGGA-
GATTTTAGTGGT-3′
Cell lines and treatment
The human colorectal cell lines HT29 (HTB-38) and
HCT116 (CCL-247) (ATCC, Manassas, VA20108, USA)
were cultured in RPMI 1640 medium (Lonza Walkers-
ville, USA). Cell lines were supplemented with 10% fetal
bovine serum (PAA laboratories GmbH, Austria). Cells
grown in 3% FBS medium were immediately treated
with sn38 (5 ng/ml, 12.5 nM) for 48 h. Note that this
treatment should be done before complete cell adhesion
so that every cell can incorporate the drug before enter-
ing the next S phase. To choose this concentration, clo-
nogenic assays were performed to determine the
concentration that kill all cells after 10 days. For
HCT116 cells, 5 ng/ml induced 100% mortality.
Chromatin Immunoprecipitation Assay (ChIP)
Cells, grown to 60% confluence, were treated or not as
i n d i c a t e da n dt h e nw a s h e da n dc r o s s - l i n k e dw i t h1 %
formaldehyde at room temperature for 8 min essentially
as previously described [16,17]. Reaction was stopped
with 10 ml of 125 mM glycin solution. Cells were
washed with cold PBS and lysed in 500 μl of lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1, 1
mM PMSF, 5 mM NaF, 5 mM Na3VO4, 2 μg/ml leu-
peptin, 5 μg/ml aprotinin, 1 μg/ml pestatin), and soni-
cated five times for 20 secondes each. Supernatants
were then recovered by centrifugation at 12 000 rpm for
10 min at 4°C, diluted once in dilution buffer (1% Triton
X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl
pH 8.1) and subjected to one round of immunoclearing
for 2 h at 4°C with 2 μg of sheared salmon-sperm DNA,
and 20 μl of proteinG-agarose coated with salmon
sperm DNA (Millipore) (of 50% slurry). Immunoprecipi-
tation was performed overnight with specific antibodies
and IgG control, and then 2 μg of sheared salmon-
sperm DNA and 20 μl of proteinG-agarose coated with
salmon sperm DNA (Millipore) (of 50% slurry) were
further added for 1 h at 4°C. Note that immunoprecipi-
tations were performed in the presence of 0,1% Igepal
CA-630. Immunoprecipitates were washed sequentially
for 10 min each in TSE I (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl),
TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20
mM Tris-HCl pH 8.1, 500 mM NaCl), and Buffer 3 (250
mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10
mM Tris-HCl pH 8.1). Beads precipitates were then
washed once with TE buffer and eluted once with 1%
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of ReChIP buffer (Dilution Buffer, 10 mM DTT) was
added to beads following washes and incubated at 37°C
for 30 minutes. The sample was then diluted 40 times
in dilution buffer and immunoprecipitations, washes and
elution were performed as before ([18]). Eluates were
heated at 65°C for 6 hours to reverse the formaldehyde
cross-linking. DNA was precipitated using classical pro-
cedures. Real-time PCR was used for ChIP analysis and
quantification. The ChIP have been calculated as bind-
ing to region of interest/IgG control, divided by binding
to negative control region/IgG control. The following
primers were used:
region -668/-400 of the Aurora A promoter: For 5′-
GAT GCCCCCTCACTATATGC-3′,R e v5 ′-AGGAGA
GAGCGGGATACCAA-3′; region -114/+161 of the Aur-
ora A promoter: For 5′-AGGTCTGGCTGGCCGTTG-
3′,R e v5 ′-CCTCGTCCGCCACTGAGATAT-3′ Control
region -1701/-1399 of the Aurora A promoter For 5′-
ACTCCAGATCCCTCAGCTTAACCA-3′ Rev 5′-CAAG
TTATGGGACGGTGAACG-3′
Other assays
Transient transfections, siRNA knockdown, RNA extrac-
tion, semi-quantitative and quantitative reverse tran-
scription-polymerase chain reaction, protein extracts
and western blots were all performed as described pre-
viously [17,19]. All experiments were performed a mini-
mum of three times before calculating means and
standard deviations as shown in figures.
Results
Topoisomerase I inhibition induced a downregulation of
Aurora-A expression
We first wanted to confirm in colorectal cell lines that
Aurora-A was mainly expressed during the G2 phase of
the cell cycle. To this end, HCT116 cells were synchro-
nized in G1/S with hydroxyurea, washed and then
grown again in serum for 5 to 13 hr. Under these condi-
tions, FACS analysis showed that cells were synchro-
nized after 8-9 hr in the G2 phase of the cell cycle and
that they enter the next G1 phase after 12-13 hr of
serum release (Figure 1A). As expected, we observed
that Aurora-A was expressed in G2, both at the protein
(Figure 1B, lanes 1-7) and mRNA levels (Figure 1B,
lanes 8-9). The same results were obtained in a second
colorectal cell line, the HT29 cells and with different
kinds of synchronization such as double thymidine
block and serum starvation (data not shown).
To determine whether topoisomerase I inhibition has
any influence on Aurora-A expression, HCT116 cells
were treated with sn38, the active metabolite of irinote-
can [15]. Under these conditions, control cells were syn-
chronized in the G2 phase of the cell cycle after 48-72
hr (Figure 1C, note that serum 9hr means G1/S syn-
chronization followed by serum stimulation for 9 hr).
Although this was the cell cycle stage when Aurora-A
expression was supposed to be maximal, results indi-
cated that the expression of the kinase was downregu-
lated in response to sn38, both at the protein (Figure
1D, compare lane 1 with lanes 2-4) and mRNA levels
(Figure 1E, normal mRNAs expression in G2 was nor-
malized to 1). As a control, the p21waf1 mRNA
increased as expected following genotoxic treatment.
Finally, these experiments have also been repeated in a
different colorectal cell line and sn38 also downregu-
lated Aurora-A in HT29 cells (data not shown and see
below Figure 2B).
Altogether, these results indicate that topoisomerase I
inhibitors such as sn38 induced a downregulation of
Aurora-A expression.
Myc binds to the promoter of the Aurora gene and is
involved in its regulation
Following sn38 treatment, we observed as expected in
HCT116 cells that p53 was stabilized and phosphory-
lated on its serine 15 residue. Consequently, p21waf1
level was also enhanced in response to drug treatment
(Figure 2A, lanes 1-4). To check whether Aurora-A
downregulation was dependent on the p53-p21 pathway
[20,21], we used the HCT116 p21-/- derivative cell line
in which both p21waf1 alleles have been deleted by
homologous recombination [22]. Results showed that
sn38 reduced Aurora-A expression in HCT116 p21-/-
cells (Figure 2B, lanes 1-4). The same effect was
observed in the HT29 cell line that contains a mutated
form of p53 (Figure 2B, lanes 5-6). These results indi-
cate that Aurora-A downregulation is not cell-type spe-
cific and is independent of the p53-p21 pathway.
During the course of this study, we noticed that the
expression of the c-Myc transcription factor was signifi-
cantly reduced following topoisomerase I inhibition (Fig-
ure 2C, lanes 1-4). This suggested that c-Myc was
involved in the regulation of the Aurora-A gene. To ver-
ify this hypothesis, we used doxycyclin-inducible expres-
sion vectors that stably drives the expression of two
different Myc siRNAs in two different clones of the
LS174T colorectal cell line. As previously shown [17],
western blot analysis showed that doxycyclin induced a
significant downregulation of c-Myc levels in the two
clones (Figure 2D, lanes 4 and 6, top panel). Interest-
ingly, we observed under these conditions that Aurora-
A expression was inhibited upon c-Myc knockdown
(Figure 2D, compare lanes 4 and 6 with lanes 3 and 5,
middle panel). Note that c-Myc downregulation did not
modify cell cycle distribution in the G2 phase of the cell
cycle (data not shown) so that Aurora-A inhibition can
not be explained by G0/G1 arrest.
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Figure 1 Topoisomerase I inhibition induced a downregulation of Aurora-A expression.A .H C T 1 1 6w e r es y n c h r o n i z e di nG 1 / Sw i t h
hydroxyurea and released for the indicated times in growth medium complemented with 3% serum. DNA content was analyzed by flow
cytometry analysis. B. Aurora-A expression was analyzed in these conditions by western blot (lanes 1-7), or quantitative RT-PCR (B, lanes 8-9)
(n = 3 +/- sd). C. HCT116 cells were synchronized in the G2 phase of the cell cycle following treatment with hydroxyurea and serum stimulation
for 9hr in growth medium (serum 9 hr) or treated with sn38 (5 ng/ml, 12.5 nM). DNA content was then analyzed by flow cytometry and
propidium iodide staining. D-E. Aurora-A expression was measured by western blot analysis (D, lanes 1-4) or quantitative RT-PCR (E) following
treatment or cell synchronisation. p21waf1 and tubulin expressions were used as controls (n = 3).
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Figure 2 Myc regulates the Aurora-A promoter. A. HCT116 cells were synchronized as above, total cell extracts were prepared and analyzed
using antibodies directed against p21waf1, p53 or its serine 15 phosphorylated form (n = 3). B. HCT116 p21-/- or HT29 cells (presenting a
mutated form of p53) were treated as described above and Aurora-A and p21waf1 expressions were measured by western blot using tubulin as
a control (n = 3). C. HCT116 cells were synchronized in the G2 phase of the cell cycle (serum 9hr) or treated with sn38 for the indicated times.
The expression of Myc and Aurora-A was analyzed by western blot on total cell extracts (n = 3). D. LS174T cells were grown in the absence or
presence of doxycyclin as indicated. Myc and Aurora expressions were then analyzed by western blot analysis (n = 3). Two different clones of
the LS174T colorectal cell line (named LS174T#1 and LS174T#2) were used, each expressing a doxycyclin-inducible expression vector that drives
the expression of different siRNAs.
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edu, we noticed that ChIP-ChIP experiments have
already suggested that Myc can potentially bind to the
Aurora-A promoter in Hela cells. Moreover, Ouyang
and collaborators have shown by ChIP-seq that both c-
Myc and N-Myc can be found associated with this gene
in embryonic stem cells [23]. Effectively, transcription
factor recognition site analysis of the Aurora-A promo-
ter revealed the presence of non canonical E-boxes that
could represent potential Myc binding sites (Figure 3A).
To determine if Myc binds to the Aurora A promoter,
its recruitment was analyzed by chromatin immunopre-
cipitation experiments (ChIP) in the LS174T cell line
described above. Results presented Figure 3B, lanes 1-4,
showed that Myc was effectively recruited to the -668/-
400 region of the Aurora-A promoter and that this was
associated with histone 3 acetylation (K9), which is indi-
cative of gene transcription. Following siRNA induction
and Myc downregulation, the binding of the transcrip-
tion factor was downregulated and this inhibition was
associated with histone H3 deacetylation (Figure 3B,
lanes 2 and 4). As a control, no binding of a control
IgG (Figure 3B, lanes 5-6), and Myc did not bind to the
5′ part of the Aurora-A promoter (data not shown).
Myc is a basic helix-loop-helix zipper transcription
factor that heterodimerizes with Max to activate gene
transcription. Its activity is inhibited by Mad which
associates with Max to recruit repressor complexes to
promoters [24]. To determine if Myc and Max are asso-
ciated with the Aurora-A promoter and if this associa-
tion is cell cycle dependent, HCT116 cells were
synchronized in G1/S with hydroxyurea, washed and
then grown again in serum for 5 hr (S/early G2), 9 hr
(G2) and 13 hr (next G1). ChIP experiments were then
performed as described above. Results presented Figure
3C, lanes 3 and 7, indicate that the two proteins are
effectively recruited to this promoter in the G2 phase of
the cell cycle. To determine if the two proteins are asso-
ciated on DNA, a serial ChIP experiment (Re-ChIP) was
then performed. For this, the soluble chromatin was
immunoprecipitated with Myc antibodies, the immune
complexes were released with DTT and the chromatin
was further divided into two aliquots and reimmunopre-
cipitated with IgG or Max antibodies. Under these con-
ditions, subsequent Re-IPs with Max antibodies were
able to immunoprecipitate the Aurora-A promoter
whereas this was not the case with the control antibody
(Figure 3D). Importantly, the association of the two pro-
teins was only detected during the G2 phase of the cell
cycle. ChIP result have been obtained by semi-quantita-
tive PCR (Figure 3D, lanes 1-4) and quantified by quan-
titative-PCR (Figure 3E). As a control, the PCR analysis
did not detect any occupancy of a control DNA region
(Figure 3D, lanes 5-8) or of the proxymal promoter
during the G1 phase of the cell cycle and at the G1/S
transition (Figure 3D, lane 4 and 1).
We concluded from these results that the Myc/Max
complex binds to the promoter of the Aurora A gene
during the G2 phase of the cell cycle and that Myc is
involved in the regulation of this gene.
Topoisomerase I inhibition prevents the association of
the Myc-Max complex with the Aurora-A promoter
To determine the links between the Myc/Max/Mad
pathway and the regulation of the Aurora-A gene fol-
lowing topoisomerase I inhibition, Max/Mad expression
was first evaluated following sn38 treatment. Whereas
no significant effect was observed on Max expression,
Mad levels increased at the protein and mRNA levels
(Figure 4A, lanes 1-2 and Figure 4B). As a control, Myc
and Aurora-A expressions were downregulated as
expected. To determine if the binding of these proteins
to the Aurora-A gene was affected by sn38, their
recruitment was analyzed by ChIP following treatment.
Results showed that the recruitment of Myc and Max
was inhibited following topoisomerase I inhibition
(Figure 4C, compare lanes 2 and 5, 7 and 9). Note that
a weak association of Myc and Max was detected in
growing conditions, probably due to the percentage
of cells, which are in the G2 phase of the cell cycle
(Figure 4C, lanes 1 and 6). Interestingly, these proteins
were also found associated with the initiation site, sug-
gesting that the upstream and initiation regions might
associate in a transcriptional loop (data not shown).
Myc and Max bindings were also inhibited on this
initiation site following sn38 treatment. To extend these
observations, ChIP experiments were then performed to
analyze the recruitment of the Mad protein. In growing
conditions or during the G2 phase of the cell cycle, Mad
was not found associated with the Aurora-A promoter.
Interestingly, when cells were treated with sn38,
this protein was significantly recruited to this gene
(Figure 4D, lanes 3-4).
Altogether, we concluded from these results that
the Myc/Max complex binds to the promoter of the
Aurora-A gene in the G2 phase of the cell cycle and
that this binding is inhibited upon topoisomerase I
inhibition.
Topoisomerase I inhibition promotes Miz-1 recruitment to
the Aurora-A promoter
The Miz-1 transcription factor is a POZ-domain-con-
taining zinc-finger proteint h a tc a nf o r mat r a n s c r i p -
tional repressor complex with Myc to inhibit gene
transcription [24]. In addition, it has also been proposed
that Miz-1 functions as a transcriptional repressor in a
Myc-independent manner through its association with
cofactors such as BCL6 or Gfi-1 [25,26]. To determine if
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Page 6 of 15Figure 3 Myc and Max are associated with the Aurora-A promoter. A. Schematic representation of the potential Myc binding sites of the
Aurora-A promoter. B. LS174T cells were treated or not with doxycyclin, soluble chromatin was immunoprecipitated with anti-Myc or anti-
acetylated-H3 polyclonal antibodies and DNA samples were then amplified using primers that cover the -668/-400 region of the Aurora-A
promoter. IgG immunoprecipitations were used as controls (n = 3 +/- sd). C. HCT116 were synchronized in G1/S with hydroxyurea and released
for the indicated times in growth medium complemented with 3% serum. Soluble chromatin was immunoprecipitated with anti-Myc or anti-
Max antibodies and DNA samples were then amplified using primers that cover the -668/-400 region of the Aurora-A promoter and quantified
as compared to IgG immunoprecipitations (n = 3 +/- sd). D, E. The association of Myc and Max on the Aurora-A promoter was analyzed by a
serial ChIP experiment. HCT116 were synchronized as described above, the soluble chromatin was immunoprecipitated with Myc antibodies,
immune complexes were released and reimmunoprecipitated with IgG or Max antibodies. DNA samples were then amplified using primers that
cover the -668/-400 region of the Aurora-A promoter and analyzed by semi-quantitative PCR (D) or quantitative PCR (E, n = 3 +/- sd).
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Figure 4 Topoisomerase I inhibition prevents the association of Myc and Max with the Aurora-A promoter.A .H C T 1 1 6w e r e
synchronized as described above and analyzed by western blot using antibodies directed against the indicated proteins (n = 3). B. Cells were
treated as described above and the mRNAs expressions of Aurora-A, Myc, Max and Mad were evaluated by quantitative RT-PCR (n = 3 +/- sd). C-
D. The association of Myc, Max and Mad with the Aurora-A promoter was analyzed in HCT116 by chromatin immunoprecipitation as described
above (n = 3 +/- sd). ChIPs were performed using extracts isolated from growing cells (C, lanes 1 and 5, D lane 1), from cells synchronized in the
G2 phase of the cell cycle (C, lanes 2 and 7, D lanes 2) or from cells treated by sn38 as indicated.
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Figure 5 Topoisomerase I inhibition induces the association of Miz-1 with the Aurora-A promoter and prevents the binding of
transcriptional coactivators. A-B. HCT116 were treated as described above and Miz-1 expression was analyzed by western blot (n = 3) or
quantitative RT-PCR (B., n = 3 +/- sd). C. ChIP analysis of Miz-1 binding to the Aurora-A promoter in growing cells (lane 1), cells synchronized in
G2 (lane 2) or following sn38 treatment. D. The recruitment on the Aurora-A promoter of CBP, RNA Pol II, HDAC1 and the acetylation of histone
H3 were analyzed by ChIP using soluble chromatin prepared from cells synchronized in the G2 phase of the cell cycle (serum 9hr, lanes 1, 3, 5
and 7) or treated with sn38 (lanes 2, 4, 6 and 8, n = 3 +/- sd).
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Page 9 of 15this protein was involved in Aurora-A inhibition, its
expression was evaluated in HCT116 cells treated or not
with sn38 (Figure 5A and 5B). Under these conditions, a
weak increase in Miz-1 protein level was observed
whereas no significant effect was detected on its mRNA
expression. ChIP experiments performed in the G2
phase of the cell cycle showed that Miz-1 was associated
with the -668/-400 region (Figure 5C, lane 2). By con-
trast, this protein was not significantly recruited to this
gene in growing cells. Interestingly, Miz-1 recruitment
was significantly increased following sn38 treatment
(Figure 5C, lanes 3-5 and data not shown). Importantly,
this binding was associated with a decreased recruitment
of the CBP transcriptional coactivator, of the RNA type
II polymerase and with a downregulation of histone H3
acetylation (Figure 5D, lanes 2, 4 and 6). We did not
observe any recruitment of the HDAC1 histone deacety-
lase to this promoter.
Altogether, we concluded from these results that
topoisomerase I inhibition induces a recruitment of
Miz-1 to the Aurora-A promoter and decreases the
binding of transcriptional coactivators.
The Aurora-A promoter is located within SAHF foci
following topoisomerase I inhibition
We have recently shown that sn38 treatment induced
senescence in colorectal cell lines (see [19,27] and text
below). Senescence is an irreversible proliferation-arrest
that is characterized by the formation of isolated hetero-
chromatin foci called Senescence Associated Hetero-
chromatin Foci (SAHF, [28]). SAHF foci contain marks
of transcriptional silencing such as heterochromatin
protein 1 (HP1) and tri-methylation of the lysine 9 of
histone H3 (H3K9Me3). During senescence, proliferative
g e n e ss u c ha sE 2 Ft a r g e t sa r ec o m p a c t e dw i t h i nt h e s e
heterochromatin foci to prevent cell cycle progression,
generally as a consequence of Rb-mediated silencing. To
extend our results, we then determined if the Aurora-A
promoter was included within these SAHFs foci. As a
first approach, we used immunofluorescence and wes-
tern blot experiments to shown that sn38 induced a glo-
b a li n c r e a s ei nH 3 K 9t r i m e t h y l a t i o ni nH C T 1 1 6c e l l s .
As expected, a significant phosphorylation of histone
H2Ax was also detected, reflecting the induction of
DNA double strand breaks following topoisomerase I
inhibition (Figure 6A and 6B). Results were quantified
by Facs analysis to show a significant increase of the
two signals (Figure 6C). DAPI staining also showed an
increase in the presence of punctuate heterochromatin
foci in the nucleus of sn38-treated cells which were not
detected in control conditions (Figure 6D). ChIP experi-
ments were then used to determine if proteins involved
in transcriptional silencing could be found associated
with the proxymal promoter of the Aurora-A gene
following treatment. Interestingly, results presented
Figure 6E, lanes 4-9, showed that HP1g was recruited to
this gene in sn38-treated cells. In addition, we also
noticed a significant increase in the amount of tri-
methylated H3K9 on the proxymal Aurora-A promoter.
By contrast, when ChIP experiments were repeated with
an antibody directed against the phosphorylated form of
histone H2AX, no signs of DNA double strand breaks
were detected within this gene.
I nl i g h to ft h e s er e s u l t s ,w ec o n c l u d e dt h a tt h eA u r -
ora-A proxymal promoter is located within SAHF foci
following genotoxic treatment and that its inhibition is
probably related to the recruitment of cofactors involved
in transcriptional silencing such as HP1g and to the tri-
methylation of H3K9.
Topoisomerase I inhibition prevents centrosome
separation
It has been shown that Aurora-A is involved in the
maturation and separation of centrosome during progres-
sion from S phase towards mitosis [29]. To determine if
topoisomerase I inhibition prevents this maturation, cen-
trosome formation was analyzed by immunofluorescence
and g-tubulin staining. When cells were synchronized in
the G2/M phase of the cell cycle, the centrosomes were
effectively stained as a doublet and Aurora-A was essen-
tially localized on the centrosomes. As expected, when
cells were treated with sn38, Aurora-A became undetect-
able by immunofluorescence (data not shown). Interest-
ingly, genotoxic treatment dit not prevent centrosome
duplication, however, no separation was observed under
these conditions (Figure 7A). Probably as a consequence
of the absence of centrosomal separation and of progres-
sion towards mitosis, we observed using clonogenic
assays that sn38 induced a complete inhibition of cell
proliferation (Figure 7B). Using beta-galactosidase stain-
ing, we also noticed an induction of senescence following
genotoxic treatment (Figure 7C).
Thus, we concluded from these results that topoi-
somerase I inhibition prevents centrosome separation,
probably as a consequence of Aurora-A inhibition, and
that this leads to G2 arrest and senescence induction.
Discussion
In this study, we have shown that the Aurora-A gene is
inhibited upon topoisomerase I inhibition. In normal
conditions, the Myc transcription factor is recruited to
the promoter of the Aurora-A gene in association with
its binding partner Max. Following topoisomerase I inhi-
bition, Mad proteins increase, the association of Myc and
Max with the Aurora-A promoter is inhibited, the Mad
and Miz-1 proteins are recruited to DNA and this is fol-
lowed by transcriptional downregulation. Probably as a
consequence of the downregulation of the Myc-Aurora A
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Page 11 of 15pathway, genotoxic treatment also prevented centrosome
separation. In light of these results, we propose that the
downregulation of the Aurora-A gene is one of the essen-
tial events of G2 arrest occurring in response to topoi-
somerase I inhibition.
Gene transcription is regulated at multiple steps
including DNA binding of transcription factors, recruit-
ment of the basal transcriptional apparatus and elonga-
tion of mRNA synthesis. Activation is also affected by
several complexes that affect nucleosomal structure [30]
such as histone acetyltransferase (HATs) proteins and
chromatin remodeling complexes. In light of our results,
we speculate that Myc is associated with Max on the
Aurora-A promoter to allow the recruitment of tran-
scriptional coactivators previously shown to be associated
with Myc, such as TRAPP, a subunit of the TIP60 histone
acetylase complex, or TIP48 and TIP49, two ATPases
involved in chromatin remodeling [31]. In addition, Myc
can also regulate the elongation program through its
association with the P-TEFb complex and cdk9 [32,33]. It
will be interesting to determine if Myc regulates the elon-
gation process on the Aurora-A gene as previously
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Figure 7 Topoisomerase I inhibition prevents centrosome separation. A. HCT116 cells synchronized or treated with sn38 as described
above were subjected to immunofluorescence analysis. Centrosomes were detected by staining with monoclonal antibody to g-tubulin. ~ 100
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Page 12 of 15reported on the cad promoter [32,33], or if its effects rely
on the recruitment of histone acetylases and chromatin
remodeling complexes. We have previously shown that
topoisomerase I inhibition induced senescence in color-
ectal cancers [19]. It has been proposed that this program
is associated with chromatin reorganization of prolifera-
tion genes into senescence-associated heterochromatin
foci (SAHFs) [28]. Silencing depends on the retinoblas-
toma pathway and is associated with enhanced histone
H3 tri-methylation and recruitment of the HP1 protein
on proliferative genes. Interestingly, we have effectively
observed that SAHFs are present in colorectal cancer
cells treated with sn38 and that topoisomerase I inhibi-
tion is associated with the recruitment of HP1g and tri-
methylation of H3K9me3 on the Aurora-A promoter.
Since Miz-1 interacts with transcriptional repressors
such as Gfi-1, Dnmt3a or BCL6 to downregulate gene
transcription [25,26,34,35], a Miz repressor complex
could inactivate the Aurora-A promoter by initiating
SAHFs formation on this gene. Since SAHFs formation
has been initially describedt ob ea s s o c i a t e dw i t ht r a n -
scriptional silencing induced by the Rb protein, our
results also suggest that this gene might be a target of
this suppressor pathway. Note however that we have not
been able to detect the expression of the p16INK4 pro-
tein in our conditions. Thus, if the Aurora-A promoter is
regulated by the Rb protein following sn38 treatment,
this does probably not rely on p16INK4.
Accumulating evidences indicate that Myc or Aurora
A overexpression is associated with chromosomal
sn38
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Figure 8 Proposed hypothesis for the role of the Myc-Aurora-A pathway in response to topoisomerase I inhibition.I nn o r m a l
conditions, the Aurora-A gene is activated and Myc binds to its promoter in association with Max. Upon treatment, sn38 binds to the
topoisomerase I and induces the formation of cleavage complexes. This induces a dowregulation of Myc and an increase in the expression of
Mad. Myc/Max binding is inhibited and Mad and/or Miz-1 binds to the Aurora-A promoter. Although this remains to be shown, we speculate
that these proteins associates with transcriptional inhibitors such as Gfi-1 or Dnmt3a to induce SAHF foci and Aurora-A downregulation. In
colorectal tumors overexpressing Myc, the Myc/Max complex remains associated with the Aurora-A promoter due to a high level of expression
and to a downregulation of Mad and Miz-1 expression. As a consequence, Aurora is overexpressed, this protein is not inhibited by
topoisomerase I inhibitors and this induces drug resistance.
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Page 13 of 15instability [10,12,36]. Since both oncogenes play an
important role in colorectal cancers, we have started to
determine if this oncogenic pathway is associated with
genomic instability in colorectal cancers. Preliminary
data indicate that the vast majority of colorectal tumors
s h o w e dah i g hd e g r e eo fa n e u p l o i d yc o r r e l a t e dw i t ha n
enhanced expression level of Myc and Aurora A. A
downregulation of Miz-1 and of the p21waf1 cell cycle
inhibitor was also observed. In light of these results, we
propose the hypothesis that the dysregulation the Myc-
Aurora A pathway is an important event leading to
genomic instability through the bypass of the G2/M
checkpoints. We speculate that tumors expressing
abnormal levels of Myc together with a high expression
of Aurora-A might be resistant to DNA-topoisomerase I
inhibitors such as irinotecan. The downregulation of the
p21waf1 protein is also probably an essential event to
allow the inactivation of the senescence program. For
this reason, we propose the hypothesis that the coordi-
nated overexpression of Myc and Aurora-A, together
with a downregulation of Miz-1 should be tested as a
prognosis signature of poor responses to topoisomerase
I inhibitors (Figure 8). This signature should help to
define in advance the subsets of tumors that will fail to
respond to chemotherapy.
Conclusions
Following DNA damage, the ATM/ATR/chk pathway is
activated to induce the upregulation of the p53 tumor
suppressor and the consequent activation of the
p21waf1 gene. In parallel, the cdc25 phosphatases are
inactivated, leading to cdk inhibition and cell cycle
arrest. Using colorectal cancer cell lines, we show that
the Aurora-A gene is also downregulated following
topoisomerase I inhibition and that this effect is prob-
ably related to a decreased recruitment of the Myc tran-
scription factor to its promoter. We propose the
hypothesis that tumors expressing high levels of the
Myc-Aurora-A pathway might be resistant to topoi-
somerase I inhibitors.
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